Loading...
Loading...
In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating on
Amarin Corporation plcAMRN, but lowered the price target from $24.00 to $20.00.
In the report, Jefferies noted, “We remain focused on the FDA panel meeting in October for ANCHOR and the launch of ANCHOR in 1H14 as the key catalysts for AMRN shares. The company remains in negotiations for a pharma partnership for ANCHOR, but also discussed the merits of self-commercialization.”
Amarin Corporation plc closed on Thursday at $5.31.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in